Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS4131 in relapsed or refractory multiple myeloma
NCT06500507Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Mar 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLS4131 in multiple myeloma (MM), sponsored by Qilu Pharmaceutical. Primary endpoints: Recommended Phase 2 Dose at 2 years and Incidence of adverse events at 2 years. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
QLS4131
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06500507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500507.